Stem Cell Therapy for Cerebral Palsy

Open Label Study of Autologous Bone Marrow Mononuclear Cells in Cerebral Palsy

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01978821

Enrollment

Registered

2013-11-08

Start date

2010-08-31

Completion date

2013-08-31

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy

Keywords

Cerebral Palsy, autologous bone marrow mononuclear cells, stem cell therapy

Brief summary

the purpose of this study was to study the effect of stem cell therapy on common symptoms of cerebral palsy patients.

Interventions

PROCEDUREAutologous bone marrow mononuclear cell transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

17 Months to 22 Years

Healthy volunteers

Inclusion criteria

* Diagnosed cases of any type of Cerebral Palsy * age above 12 months.

Exclusion criteria

* presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[Hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia.

Design outcomes

Primary

Measure	Time frame
Change in clinical symptoms of cerebral palsy after 6 months	Six months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026